Novoheart is pleased to announce the opening of its brand new Hong Kong facility consisting of 5,300 ft² of integrated laboratory and office space. Located in the Hong Kong Science Park, the laboratory is equipped with state-of-the-art facilities for stem cell production, tissue engineering and world-class research and development. The facility provides Novoheart with a new level of scalability enabling it to accommodate a significant number of additional revenue-generating commercial contracts and projects.
With the newly expanded Hong Kong facilities, operations are being streamlined to ensure its growing R&D team works seamlessly with those located in Irvine, California location, and the two locations enable R&D programs to operate continuously round the clock. In addition to this facility being an advantage for global clients, Novoheart will continue to deliver best-in-class drug discovery tools for pharmaceutical and biotech clients.
For the detailed press release, please click here.